DPP-4
Boehringer cheered by diabetes data
June 28, 2010Research and Development Boehringer, DPP-4, diabetes, linagliptin
Boehringer Ingelheim has been cheered by phase III data showing its new oral once-daily type II diabetes tablet linagliptin significantly …
Five-year cardiovascular study planned for Onglyza
March 10, 2010Research and Development, Sales and Marketing DPP-4, Onglyza, diabetes
Bristol-Myers Squibb and AstraZeneca are to embark on a five-year study of Onglyza in type II diabetes patients who may …
Boehringer prepares for diabetes launch
December 3, 2009Medical Communications Boehringer, DPP-4, diabetes
Boehringer Ingelheim has hired the London arm of international PR agency Weber Shandwick to handle the UK launch of its …
AZ-BMS launch Onglyza in Europe
October 19, 2009Sales and Marketing AZ, BMS, DPP-4, Onglyza, diabetes
Bristol-Myers Squibb and AstraZeneca’s long-awaited type II diabetes drug Onglyza has been launched in the UK, its first European market.Designed …
Latest content
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
